EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer

Sydney A Caputo iD, Madeline Hawkins, Ellen B Jaeger, William Fleming, Crystal Casado, Charlotte Manogue, Minqi Huang, Alex Lieberman, Malcolm Light, Isabelle P Sussman, Patrick Miller, Pedro C Barata und 5 weitere

The Prostate · 2023

DOI: 10.1002/pros.24529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Sydney A Caputo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Tulane University School of Medicine, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bipolar androgen therapy (BAT) is a novel therapy known to be effective in a subset of men with metastatic castrate resistant prostate cancer (mCRPC). A better understanding of responders and nonresponders to BAT would be useful to clinicians considering BAT therapy for patients. Herein we analyze clinical and genetic factors in responders/nonresponders to better refine our understanding regarding which patients benefit from this innovative therapy. Methods mCRPC patients were assessed for response or no response to BAT. Patients with PSA declines of greater than 50% from baseline after 2 or more doses of testosterone were considered to be responders. Whereas, nonresponders had no PSA decline after 2 doses of testosterone and subsequently manifest a PSA increase of >50%. Differences between these two groups of patients were analyzed using clinical and laboratory parameters. All patients underwent genomic testing using circulating tumor DNA (ctDNA) and germline testing pre‐BAT.

Results

Twenty five patients were nonresponders and 16 were responders. Baseline characteristics between nonresponders and responders varied. Responders were more likely to have had a radical prostatectomy as definitive therapy and were more likely to have been treated with an androgen receptor (AR) antagonist (enzalutamide or apalutamide) immediately before BAT (compared to abiraterone). Duration of prior enzalutamide therapy was longer in responders. Nonresponders were more likely to have bone‐only metastases and responders were more likely to have nodal metastases. Assays detected ctDNA AR amplifications more often in responding patients. Responders trended toward having the presence of more TP53 mutations at baseline.

Conclusions

BAT responders are distinct from nonresponders in several ways however each of these distinctions are imperfect. Patterns of metastatic disease, prior therapies, duration of prior therapies, and genomics each contribute to an understanding of patients that will or will not respond. Additional studies are needed to refine the parameters that clinicians can utilize before choosing among the numerous treatment alternatives available for CRPC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansAndrogensPhenylthiohydantoinNitrilesTestosteroneAndrogen Receptor AntagonistsProstate-Specific AntigenReceptors, AndrogenBenzamides

Stichwörter der Autor:innen

BATCRPCctDNAprostate cancertestosterone

Substanzen

AndrogensPhenylthiohydantoinNitrilesTestosteroneAndrogen Receptor AntagonistsProstate-Specific AntigenReceptors, AndrogenenzalutamideBenzamides

Autor:innen und Institutionen

  • Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Tulane Cancer Center, New Orleans, Louisiana, USA.
  • University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.

ORCID-Profile: Sydney A Caputo, Elisa M Ledet, Emmanuel S Antonarakis, Oliver Sartor

Zitieren

APA

Caputo, S. A., Hawkins, M., Jaeger, E. B., Fleming, W., Casado, C., Manogue, C., Huang, M., Lieberman, A., Light, M., Sussman, I. P., Miller, P., Barata, P. C., Lewis, B. E., Layton, J. L., Ledet, E. M., Antonarakis, E. S., & Sartor, O. (2023). Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer. The Prostate. https://doi.org/10.1002/pros.24529

Vancouver

Caputo SA, Hawkins M, Jaeger EB, Fleming W, Casado C, Manogue C, et al. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer. The Prostate. 2023. doi:10.1002/pros.24529

BibTeX
@article{Caputo2023,
  author = {Caputo, Sydney A and Hawkins, Madeline and Jaeger, Ellen B and Fleming, William and Casado, Crystal and Manogue, Charlotte and Huang, Minqi and Lieberman, Alex and Light, Malcolm and Sussman, Isabelle P and Miller, Patrick and Barata, Pedro C and Lewis, Brian E and Layton, Jodi Lyn and Ledet, Elisa M and Antonarakis, Emmanuel S and Sartor, Oliver},
  title = {Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24529}
}
Kostenlos starten →